Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
4,346 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00257608 | A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS) | completed | Phase 3 | 1,145 | Genentech, Inc.INDUSTRY | 17 | Apr 18, 2016 | clinicaltrials |
| NCT01475006 | AMG 595 First-in-Human in Recurrent Gliomas | completed | Phase 1 | 32 | AmgenINDUSTRY | 2 | Apr 15, 2016 | clinicaltrials |
| NCT01395017 |
| Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer(LAPC) |
| completed |
| Phase 2 |
| 202 |
| Otsuka Pharmaceutical Development & Commercialization, Inc.INDUSTRY |
| 15 |
| Apr 8, 2016 |
| clinicaltrials |
| NCT00338247 | EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer | approved for marketing | — | — | NovartisINDUSTRY | 45 | Apr 6, 2016 | clinicaltrials |
| NCT02234297 | Safety Study of BLZ-100 in Adult Subjects With Glioma Undergoing Surgery | completed | Phase 1 | 17 | Blaze Bioscience Inc.INDUSTRY | 2 | Apr 6, 2016 | clinicaltrials |
| NCT02221505 | Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia | terminated | Phase 1 | 3 | Novartis PharmaceuticalsINDUSTRY | 4 | Apr 5, 2016 | clinicaltrials |
| NCT02723071 | A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL) | completed | Phase 1 / Phase 2 | 48 | Hoffmann-La RocheINDUSTRY | 6 | Mar 30, 2016 | clinicaltrials |
| NCT00188331 | Cognitive Function and Fatigue in Colorectal Cancer (CRC) Patients After Chemotherapy | completed | — | 441 | University Health Network, TorontoOTHER | 2 | Mar 22, 2016 | clinicaltrials |
| NCT01403636 | A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia | completed | Phase 2 | 167 | SanofiINDUSTRY | 6 | Mar 17, 2016 | clinicaltrials |
| NCT00634088 | Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer | terminated | Phase 1 | 13 | R-PharmINDUSTRY | 3 | Mar 10, 2016 | clinicaltrials |
| NCT00152854 | Acetaminophen for Cancer Pain | completed | Phase 3 | 12 | University Health Network, TorontoOTHER | 2 | Mar 8, 2016 | clinicaltrials |
| NCT01254188 | Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients(ENESTxtnd) | completed | Phase 3 | 421 | Novartis PharmaceuticalsINDUSTRY | 19 | Mar 3, 2016 | clinicaltrials |
| NCT01325688 | PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities | completed | Phase 2 | 75 | PeplinINDUSTRY | 1 | Feb 26, 2016 | clinicaltrials |
| NCT00005945 | Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia | completed | Phase 3 | 3,054 | Children's Oncology GroupNETWORK | 5 | Feb 23, 2016 | clinicaltrials |
| NCT01488565 | A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia(Aza-E) | completed | Phase 2 | 25 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Feb 15, 2016 | clinicaltrials |
| NCT01500538 | A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)(VEIL) | terminated | Phase 2 | 1 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Feb 15, 2016 | clinicaltrials |
| NCT01697072 | First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma(RILOMET-1) | terminated | Phase 3 | 609 | AmgenINDUSTRY | 27 | Feb 9, 2016 | clinicaltrials |
| NCT00554229 | A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases(ENTHUSE M1) | completed | Phase 3 | 896 | AstraZenecaINDUSTRY | 31 | Feb 8, 2016 | clinicaltrials |
| NCT00334282 | Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma | completed | Phase 3 | 435 | GlaxoSmithKlineINDUSTRY | 25 | Feb 5, 2016 | clinicaltrials |
| NCT00789828 | Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)(EXIST-1) | completed | Phase 3 | 117 | Novartis PharmaceuticalsINDUSTRY | 10 | Feb 3, 2016 | clinicaltrials |
| NCT00546611 | The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s) | withdrawn | Phase 1 | 0 | PeplinINDUSTRY | 1 | Jan 28, 2016 | clinicaltrials |
| NCT00333775 | A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer | completed | Phase 3 | 736 | Hoffmann-La RocheINDUSTRY | 24 | Jan 27, 2016 | clinicaltrials |
| NCT00982488 | Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia(START rollover) | completed | Phase 2 | 238 | Bristol-Myers SquibbINDUSTRY | 24 | Jan 22, 2016 | clinicaltrials |
| NCT00681122 | CARIATIDE (Compliance of ARomatase Inhibitors AssessmenT In Daily Practice Through Educational Approach)(CARIATIDE) | completed | — | 2,600 | AstraZenecaINDUSTRY | 18 | Jan 18, 2016 | clinicaltrials |
| NCT00280878 | Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma | completed | Phase 2 | 12 | Bayside HealthOTHER_GOV | 1 | Jan 15, 2016 | clinicaltrials |
| NCT00163644 | RCT to Investigate Whether an Exercise Programme Improves the Physical Performance and QOL After BMT | unknown | N/A | 66 | Bayside HealthOTHER_GOV | 1 | Jan 8, 2016 | clinicaltrials |
| NCT00163748 | Efficacy and Treatment Related Toxicity Study of a New Regimen for Lymphoma | completed | Phase 2 | 40 | Bayside HealthOTHER_GOV | 1 | Jan 8, 2016 | clinicaltrials |
| NCT00163761 | Efficacy Study of Outpatient Therapy for Lymphoma | completed | Phase 2 | 90 | Bayside HealthOTHER_GOV | 1 | Jan 8, 2016 | clinicaltrials |
| NCT00080873 | Traumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell Transplantation | completed | N/A | 195 | Children's Oncology GroupNETWORK | 4 | Jan 7, 2016 | clinicaltrials |
| NCT02643511 | Hemiablative Focal Brachytherapy Pilot Study | unknown | Phase 2 | 20 | St George Hospital, AustraliaOTHER | 1 | Dec 31, 2015 | clinicaltrials |
| NCT01028222 | A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation(TEAM) | completed | Phase 2 | 55 | Novartis PharmaceuticalsINDUSTRY | 14 | Dec 30, 2015 | clinicaltrials |
| NCT01140347 | A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib(REACH) | completed | Phase 3 | 565 | Eli Lilly and CompanyINDUSTRY | 27 | Dec 28, 2015 | clinicaltrials |
| NCT01624493 | BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients | withdrawn | Phase 1 / Phase 2 | 0 | Hoosier Cancer Research NetworkOTHER | 3 | Dec 23, 2015 | clinicaltrials |
| NCT01263886 | Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer(DISRUPT) | completed | Phase 2 | 176 | SanofiINDUSTRY | 13 | Dec 21, 2015 | clinicaltrials |
| NCT01360840 | EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer(PERSEUS) | completed | Phase 2 | 180 | EMD SeronoINDUSTRY | 12 | Dec 14, 2015 | clinicaltrials |
| NCT01056341 | Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy | completed | Phase 2 / Phase 3 | 512 | Pierre Fabre DermatologyINDUSTRY | 16 | Dec 10, 2015 | clinicaltrials |
| NCT00389155 | First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy | completed | Phase 2 / Phase 3 | 34 | Bristol-Myers SquibbINDUSTRY | 16 | Dec 7, 2015 | clinicaltrials |
| NCT01223027 | Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma | completed | Phase 3 | 564 | Novartis PharmaceuticalsINDUSTRY | 27 | Dec 7, 2015 | clinicaltrials |
| NCT00409188 | Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)(START) | completed | Phase 3 | 1,513 | EMD SeronoINDUSTRY | 33 | Nov 20, 2015 | clinicaltrials |
| NCT01211691 | Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF) | suspended | Phase 1 / Phase 2 | 120 | Humanigen, Inc.INDUSTRY | 2 | Nov 17, 2015 | clinicaltrials |
| NCT02051868 | International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel(InterAACT) | unknown | Phase 2 | 80 | Royal Marsden NHS Foundation TrustOTHER | 3 | Nov 4, 2015 | clinicaltrials |
| NCT00879333 | Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)(GRANITE-1) | completed | Phase 3 | 656 | Novartis PharmaceuticalsINDUSTRY | 22 | Nov 3, 2015 | clinicaltrials |
| NCT02189824 | Chemotherapy Followed by Infusion of Partially HLA Matched Unrelated Donor Cells for Patients With AML Who Are Ineligible for Stem Cell Transplantation(SCRAMBLE) | unknown | Phase 1 | 12 | University of SydneyOTHER | 1 | Nov 2, 2015 | clinicaltrials |
| NCT01033019 | To Evaluate the Safety, Local Tolerability, PK and PD of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas (sBCC) | terminated | Phase 2 | 25 | Novartis PharmaceuticalsINDUSTRY | 2 | Oct 30, 2015 | clinicaltrials |
| NCT00511459 | Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients | completed | Phase 2 | 228 | AmgenINDUSTRY | 13 | Oct 29, 2015 | clinicaltrials |
| NCT00560235 | Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors | completed | Phase 1 / Phase 2 | 138 | PfizerINDUSTRY | 11 | Oct 28, 2015 | clinicaltrials |
| NCT00932126 | This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors | terminated | Phase 1 | 35 | PfizerINDUSTRY | 2 | Oct 28, 2015 | clinicaltrials |
| NCT01121575 | A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer | completed | Phase 1 | 70 | PfizerINDUSTRY | 2 | Oct 28, 2015 | clinicaltrials |
| NCT01234311 | A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer | completed | Phase 3 | 1,245 | Active Biotech ABINDUSTRY | 37 | Oct 21, 2015 | clinicaltrials |
| NCT00103506 | Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma | completed | Phase 3 | 646 | Janssen Research & Development, LLCINDUSTRY | 17 | Oct 19, 2015 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials